SCHEDULE 13G/A: BlackRock Discloses 1.7% Stake in Tenaya Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in Tenaya Therapeutics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,732,800 shares of Tenaya Therapeutics, Inc. Common Stock.
- This represents 1.7% of the total outstanding shares of the class of securities.
- BlackRock holds sole voting power over 2,714,680 shares and sole dispositive power over 2,732,800 shares.
- The shares are held through various BlackRock business units, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
- This filing is an Amendment No. 2 to a Schedule 13G, with the event date requiring the filing being June 30, 2025.
Sentiment
Score: 5
Explanation: The document is a routine Schedule 13G filing disclosing institutional ownership, which is a factual report and does not convey positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- BlackRock, a major institutional investor, maintains a significant stake in Tenaya Therapeutics, indicating continued investment interest.
Negatives
- No specific negative information regarding Tenaya Therapeutics' performance or outlook is present in this ownership disclosure.
Risks
- No specific risks related to Tenaya Therapeutics' operations or financial health are mentioned in this Schedule 13G filing.
Future Outlook
No forward-looking statements or guidance regarding Tenaya Therapeutics' business or financial performance are provided in this ownership disclosure.
Management Comments
- BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector. It reflects an investment decision by a major asset manager in a specific company.
Comparison to Industry Standards
- This document does not provide financial or operational results for Tenaya Therapeutics that could be compared to industry benchmarks or specific comparable companies or projects. It is solely a disclosure of institutional ownership.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holding, which can influence investor perception regarding the company's attractiveness to large funds.
Next Steps
- No specific future actions, events, or milestones for Tenaya Therapeutics are mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/16/2025 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Tenaya Therapeutics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.